PRECIGEN, INC. Retained Earnings
PRECIGEN, INC. (PGEN) had Retained Earnings of -$2.33 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-04
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$2.33B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$2.35B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$2.34B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$2.32B.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$2.33B 10-Q · filed 2026-08-04 | |
| 2026-03-31 | -$2.35B 10-Q · filed 2026-05-13 | |
| 2025-12-31 | -$2.34B 10-Q · filed 2026-08-04 | |
| 2025-09-30 | -$2.32B 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$2.17B 10-Q · filed 2025-08-12 | |
| 2025-03-31 | -$2.14B 10-Q · filed 2025-05-14 | |
| 2024-12-31 | -$2.09B 10-K · filed 2026-03-25 | |
| 2024-09-30 | -$2.07B 10-Q · filed 2024-11-14 | |
| 2024-06-30 | -$2.05B 10-Q · filed 2024-08-14 | |
| 2024-03-31 | -$1.99B 10-Q · filed 2024-05-14 | |
| 2023-12-31 | -$1.96B 10-K · filed 2025-03-19 | |
| 2023-09-30 | -$1.93B 10-Q · filed 2023-11-09 | |
| 2023-06-30 | -$1.91B 10-Q · filed 2023-08-09 | |
| 2023-03-31 | -$1.89B 10-Q · filed 2023-05-10 | |
| 2022-12-31 | -$1.87B 10-K · filed 2024-03-19 | |
| 2022-09-30 | -$1.85B 10-Q · filed 2022-11-09 | |
| 2022-06-30 | -$1.93B 10-Q · filed 2022-08-08 | |
| 2022-03-31 | -$1.92B 10-Q · filed 2022-05-09 | |
| 2021-12-31 | -$1.92B 10-K · filed 2023-03-06 | |
| 2021-09-30 | -$1.89B 10-Q · filed 2021-11-08 | |
| 2021-06-30 | -$1.86B 10-Q · filed 2021-08-09 | |
| 2021-03-31 | -$1.84B 10-Q · filed 2021-05-10 | |
| 2020-12-31 | -$1.82B 10-K · filed 2022-03-01 | |
| 2020-09-30 | -$1.78B 10-Q · filed 2020-11-09 | |
| 2020-06-30 | -$1.75B 10-Q · filed 2020-08-10 | |
| 2020-03-31 | -$1.71B 10-Q · filed 2020-05-11 | |
| 2019-12-31 | -$1.65B 10-K · filed 2021-03-01 | |
| 2019-09-30 | -$1.48B 10-Q · filed 2019-11-12 | |
| 2019-06-30 | -$1.43B 10-Q · filed 2019-08-09 | |
| 2019-03-31 | -$1.39B 10-Q · filed 2019-05-09 | |
| 2018-12-31 | -$1.33B 10-K · filed 2020-03-02 | |
| 2018-09-30 | -$990.08M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | -$932.76M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | -$867.37M 10-Q/A · filed 2018-08-13 | -$930.22M 10-Q · filed 2018-05-10 |
| 2017-12-31 | -$847.82M 10-K · filed 2019-03-01 | |
| 2017-09-30 | -$820.55M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | -$780.87M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | -$762.20M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | -$729.34M 10-K · filed 2018-03-01 | |
| 2016-09-30 | -$685.20M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | -$656.22M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | -$607.16M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | -$542.73M 10-K · filed 2017-03-01 | |
| 2015-09-30 | -$510.01M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | -$471.80M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | -$431.14M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | -$458.24M 10-K · filed 2016-02-29 | |
| 2014-09-30 | -$477.07M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | -$424.34M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | -$372.30M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | -$376.41M 10-K · filed 2015-03-02 | |
| 2013-09-30 | -$364.21M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | -$376.16M 10-Q/A · filed 2013-10-21 | |
| 2012-12-31 | -$321.55M 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |